MedTrace Logo

A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults

NCT00945893 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2011-09-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine the safety and descriptive immunogenicity of the H1N1 influenza vaccine in healthy adults.

Conditions

  • Healthy

Interventions

BIOLOGICAL

MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]

0.5 mL; (intranasal sprayer)

OTHER

Placebo

(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)

Sponsors & Collaborators

Principal Investigators

  • Raburn Mallory, M.D. · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-09-30
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00945893 on ClinicalTrials.gov